Company Culture

Quote


































































EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ™ for Posterior Segment Uveitis to be Presented at the 36th Annual Scientific Meeting of the American Society of Retina Specialists
 






anonymous said:
https://www.nasdaq.com/symbol/alim/insider-trades
Click to expand...

We have incurred significant losses since our inception in June 2003. As of March 31, 2018, we had accumulated a deficit of $406.8 million. We expect to incur substantial losses through the continued commercialization of ILUVIEN as we:
•
continue the commercialization of ILUVIEN in the U.S. and EEA, where we sell direct, and in other countries in the EEA and the Middle East, where we sell through our distributors;
•
continue to seek regulatory approval of ILUVIEN for other indications and in other jurisdictions;
•
evaluate the use of ILUVIEN for the treatment of other diseases; and

•
advance the clinical development of any future products or product candidates either currently in our pipeline, or that we may license or acquire in the future.
As of March 31, 2018, we had approximately $20.3 million in cash and cash equivalents.
On January 5, 2018, we entered into a $40.0 million Loan and Security Agreement (2018 Loan Agreement) with Solar Capital Ltd. (Solar Capital). Under the 2018 Loan Agreement, we borrowed the entire $40.0 million as a term loan that matures on July 1, 2022.
We used the proceeds of the 2018 Loan Agreement loan to refinance and pay off the previous loan agreement with Hercules Capital, Inc. (Hercules Loan Agreement) and to pay closing expenses associated with the 2018 Loan Agreement. We used the remaining loan proceeds to provide additional working capital for general corporate purposes. (See Note 10 of our notes to condensed consolidated financial statements).
Our revenues for the three months ended March 31, 2018 and 2017 were generated from product sales primarily in the U.S., Germany, Portugal and the United Kingdom. In the U.S., two large pharmaceutical distributors accounted for 71% and 67% of our consolidated revenues for the three months ended March 31, 2018 and 2017, respectively. These distributors purchase ILUVIEN from us, maintain inventories of ILUVIEN and sell downstream to physician offices, pharmacies and hospitals. Internationally, in countries where we sell direct, our customers are hospitals, clinics and pharmacies. We sometimes refer to physician offices, pharmacies, hospitals and clinics as end users. In international countries where we sell to distributors, these distributors maintain inventory levels of ILUVIEN and sell to their customers.
 






now there is not one unit sale in germany, so they wanted the hole team fired in good old germany. but they can‘t because they didn‘t get some idiots for the job.
today they hired some loser from B&L , plastic surgery. they didn‘t sale anything.
And in UK they din‘t get a reimbursment for uveitis.
My advice , run and don‘t Look back , your Stocks sucks
PAO
 










































Top Bottom
Back
Quote